You are now leaving Amgen's website www.amgencare.ie and entering another website. Amgen is not responsible for the content of this third-party website you are entering now and is not adopting such content into this website. If you want to leave www.amgencare.ie please click continue:

Return to Previous Page Continue

Neulasta^® (pegfilgrastim) - information for patients

This site is designed to provide patients who have been prescribed Neulasta^® (pegfilgrastim) with information about your treatment and other useful materials. Should you have any concerns or questions regarding your treatment with Neulasta^®, please speak to your doctor, pharmacist or nurse.

About Neulasta^®

About Neulasta^®

Click the links below to learn more about Neutropenia and Neulasta^®.

Why have you been prescribed Neulasta^®?

Learn more

Infection - signs and how to help reduce the risk

Learn more

Considerations before starting Neulasta^®

Learn more

Possible side effects

Learn more

How is Neulasta^® injected?

Learn more

How to store Neulasta^®

Learn more

More Resources

Learn more

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Side effects can be reported directly to the Health Products Regulatory Authority (HPRA) using the available methods via www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine. Side effects should also be reported to Amgen Limited on +44 (0) 1223 436441 or Freephone 1800 535 160.

Please report any potential quality issue with the Amgen product you have received, by calling us on +44 (0) 1223 436441 or Freephone 1800 535 160 and providing us with the details. Please ensure that you keep your packaging, so we are able to identify your product more easily.

For a list of possible side effects, please see

Patient Information Leaflet (PIL)

About Neulasta®

Reporting of side effects:

About Neulasta^®